3-V Biosciences is a biopharmaceutical company focused on discovering and developing novel therapeutics that modulate key pathways for the treatment of oncology and infectious disease.
3-V was founded around an innovative platform that identifies drug targets through an initial antiviral lens. We utilize an integrated discovery approach that harnesses rigorous, innovative science coupled with best practices honed through years of experience in drug discovery and development.
We begin by looking beyond typical infectious disease targets to solutions that exploit a virus’ dependency on host pathways. Targeting these interactions has two key advantages:
- Generating new classes of antiviral therapeutics with broad- spectrum activity and a high barrier to resistance; and
- Generating programs with multiple potential indications from a single discovery.
3-V’s platform has produced a series of targets in virology and oncology. In preclinical testing, our lead oncology program targeting fatty acid synthase (FASN) has demonstrated potent activity against multiple tumor types. The antiviral leads in our pipeline are characterized by their novel mechanism of action, broad-spectrum antiviral activity and high barrier to resistance. 3-V is currently evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV).